Bragar Eagel & Squire is Investigating Certain Officers and Directors of Merit Medical Systems, Clover Health, and Zoom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Dow ends at record high, Nasdaq falls as tech slides
- Trump's Facebook (FB) Ban Upheld, Oversight Board Asks Company to Come Up With a 'Proportionate Response' Going Forward
- PayPal (PYPL) Tops Q1 EPS by 21c, Offers Q2 and FY Guidance
- Peloton (PTON) Plunges After Recalling All Treadmills, Analyst Says Will Negatively Impact Broader Tread Rollout
- T-Mobile (TMUS) Gains After Topping Q1 Consensus as 5G Story Accelerates, 'More to Come' Says Analyst
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
NEW YORK, April 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Merit Medical Systems, Inc. (NASDAQ: MMSI), Clover Health Investments Corp. (NASDAQ: CLOV), and Zoom Video Communications, Inc. (NASDAQ: ZM) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
Merit Medical Systems, Inc. (NASDAQ: MMSI)
Bragar Eagel & Squire is investigating certain officers and directors of Merit Medical Systems, Inc. following news that the Shareholder Class Action against Merit Medical has survived the motions to dismiss in the pending securities class action and may face damages.
According to the securities class action complaint, during the class period defendants made false and misleading statements and/or failed to disclose adverse information concerning Merit’s business and prospects. Specifically, defendants failed to disclose that: (a) the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019; and (c) in light of the foregoing, the Company’s reported financial guidance for fiscal 2019 and 2020 was made without a reasonable basis. As a result of defendants’ material misrepresentations and omissions, Merit stock traded at artificially inflated prices of more than $62 per share. On March 29, 2021, U.S. District Judge David O. Carter denied defendants’ motions to dismiss plaintiffs’ claims, finding that plaintiffs had plausibly alleged securities fraud claims.
For more information on our investigation into Merit Medical go to: https://bespc.com/cases/mmsi
Clover Health Investments Corp. (NASDAQ: CLOV)
Bragar Eagel & Squire is investigating certain officers and directors of Clover Health Investments Corp. following a class action complaint that was filed against Clover on February 5, 2021.
The complaint alleges that throughout the class period defendants made materially false and misleading statements regarding the Company’s business. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Clover was the recipient of a Civil Investigative Demand from the DOJ; (ii) much of Clover’s sales are driven by a major related party deal that Clover not only failed to disclose but took active steps to conceal; (iii) Clover’s subsidiary Seek Insurance failed to disclose its relationship with Clover and misled consumers as to its purported independence; (iv) Clover’s software was in fact rudimentary; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
For more information on our investigation into Clover go to: https://bespc.com/cases/clover
Zoom Video Communications, Inc. (NASDAQ: ZM)
Bragar Eagel & Squire is investigating certain officers and directors of Zoom Video Communications, Inc. following a class action complaint that was filed against Zoom on April 7, 2020.
The Complaint alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Zoom had inadequate data privacy and security measures; (ii) contrary to Zoom’s assertions, the Company’s video communications service was not end-to-end encrypted; (iii) as a result of all the foregoing, users of Zoom’s communications services were at an increased risk of having their personal information accessed by unauthorized parties, including Facebook; (iv) usage of the Company’s video communications services was foreseeably likely to decline when the foregoing facts came to light; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
For more information on our investigation into Zoom go to: https://bespc.com/cases/ZM
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire is Investigating Certain Officers and Directors of Merit Medical Systems, Ebix, Inc., and Zoom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Global Public Health Convention Study in The Lancet Redefines the Future of Pandemics, says GPHC Panel
- Bird Canada Disappointed in City of Toronto e-Scooter Pilot Decision
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!